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Orthopoxvirus
VaccineModiﬁed vaccinia virus Ankara (MVA), which is a promising replication-defective vaccine vector, is unusual
among the orthopoxviruses in activating NF-κB transcription factors in cells of several types. In human
embryonic kidney (HEK 293T) cells, the MVA-induced depletion of IκBα required to activate NF-κB is
inhibited by UV-inactivation of the virus, and begins before viral DNA replication. In HEK 293T, CHO, or RK13
cells, expression of the cowpox virus CP77 early gene, or the vaccinia virus K1L early gene suppresses MVA-
induced IκBα depletion. In mouse embryonic ﬁbroblasts (MEFs), MVA induction of IκBα depletion is
dependent on the expression of mouse or human double-stranded RNA-activated protein kinase (PKR).
These results demonstrate that events during the early phase of MVA replication can induce PKR-mediated
processes contributing both to the activation of NF-κB signaling, and to processes that may restrict viral
replication. This property may contribute to the efﬁcacy of this vaccine virus.Introduction
The cellular response to viral infection usually involves major
changes in host gene expression to effect the suppression of viral
replication by the induction of immune responses. However, the
various mechanisms that enable cells to sense viral infections and
respond in this way are not completely understood.
Some of the most important effectors of virus-induced changes in
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ll rights reserved.transcription factors (reviewed by Hayden et al. (2006)). These
transcription factors are activated in response to a wide variety of
stimuli, including pathogen-associated molecular patterns (PAMPs),
as well as other components of immune responses (reviewed by
Carmody and Chen (2007); Doyle and O'Neill (2006); Meylan and
Tschopp (2006)). The NF-κB transcription factors are held inactive by
their association with Inhibitor of κB (IκB) proteins. The classical
pathway of activation of NF-κB involves the phosphorylation and
degradation of the IκB proteins. This allows the released NF-κB
transcription factors to bind to DNA, and then induce the transcrip-
tion of a wide range of genes, including many of critical importance
in immune responses, cell proliferation, and apoptosis (reviewed by
Hoffmann and Baltimore (2006); Perkins and Gilmore (2006)).
Viruses of many types have acquired mechanisms to inhibit the
antiviral effects of NF-κB activation, though some viruses exploit NF-
κB activation for their own replicative purposes (reviewed by Hiscott
et al. (2001); Hiscott et al. (2006)). The orthopoxviruses appear to be
primarily in the former group, encoding several proteins that act in
various ways to prevent NF-κB activation. These viral proteins in-
clude the following: secreted receptors for interleukin (IL)-1β, tumor
Fig.1. (A)MVA-induced IκBα depletion is transient and begins during the early phase of
viral replication. HEK 293T cells were mock infected (M) with PBS or infected with MVA
(20 pfu/cell). At the indicated times post-infection, cells were harvested and
cytoplasmic extracts were prepared. Proteins in the extracts were resolved by PAGE,
and transferred to nitrocellulose membranes. IκBα was detected with rabbit antibody
against human IκBα and visualized by ECL. Equal protein loading and the efﬁcient
transfer of proteins to the membrane were veriﬁed using the ﬂuorescent SYPRO Total
Protein Stain. (B) Inhibition of DNA synthesis does not affect MVA-induced IκBα
depletion. At the start of the infection, HEK 293T cells were either treated with 40 ng/ml
of cytosine arabinoside (AraC), or left untreated. Cellsweremock infected (M)with PBS, or
infected with MVA (20 pfu/cell). At the indicated times post-infection, cells were
harvested, and the depletion of IκBα was monitored as described in panel A. (C) Virus-
induced IκBα depletion is reduced in MVA-infected cells when protein synthesis is
inhibited with cycloheximide. At the start of infection, HEK 293T cells were either treated
with 100 μg/ml cycloheximide (CHX), or left untreated. Cellsweremock infected (M)with
PBS, or infected with MVA (20 pfu/cell). At the indicated times post-infection, cells were
harvested, and the depletion of IκBα was monitored as described in panel A. The
membrane was subsequently processed for the detection of GAPDH as an additional
control for protein loading per lane.
178 H.E. Lynch et al. / Virology 391 (2009) 177–186necrosis factor (TNF), IL-18, and CD30L, each of which are cytokines
that can activate NF-κB; an inhibitor of the IL-1 β processing enzyme
(caspase-1) needed for the processing, activation and secretion of
both IL-1 and IL-18; and several inhibitors of components of the IL-1/
Toll-like receptor signaling pathways (reviewed by Moss and Shisler
(2001); Seet et al. (2003)).
Previously, we showed that orthopoxviruses of several types,
namely vaccinia viruses Western Reserve (VV-WR) and Copenhagen
(VV-Cop), cowpox virus Brighton red (CPXV-BR), and raccoonpox
virus V71-I-85A (RCN), each failed to induce NF-κB signaling upon
infection of HEK 293 cells. In addition, each of these viruses inhibited
TNF-mediated induction of NF-κB signaling, suggesting that these
viruses encoded one or more inhibitors of TNF signaling pathways. In
marked contrast, the modiﬁed vaccinia virus Ankara (MVA) strain
induced NF-κB signaling upon infection of HEK 293 cells (Oie and
Pickup, 2001). These results suggested that MVA, which lacks
functional versions of many of the accessory genes found in other
orthopoxviruses (Antoine et al., 1998), might either lack genes
encoding inhibitors of NF-κB signaling, or have a greater propensity
to induce NF-κB signaling than some of the other orthopoxviruses, or
possess a combination of both properties (Oie and Pickup, 2001).
Several studies have now shown that MVA lacks several of the
inhibitors of NF-κB signaling encoded by other orthopoxviruses. MVA
does not encode any of the ﬁve inhibitory members of the TNF
receptor family encoded by other orthopoxviruses (Hu et al., 1994;
Loparev et al., 1998; Panus et al., 2002; Saraiva and Alcami, 2001;
Smith et al., 1996). It does not encode a version of the vaccinia virus
A52R protein that can interact with IL-1 receptor associated kinase
(IRAK2) and TNF associated factor 6 (TRAF6) to inhibit IL-1/Toll-like
receptor induced NF-κB signaling pathways (Bowie et al., 2000; Harte
et al., 2003). Shisler and Jin (2004) have shown that repair of the
disrupted MVA K1L gene can reduce MVA-mediated induction of NF-
κB signaling. The N1 protein, which has been found to be capable of
associating with components of the IκB kinase complex and suppres-
sing NF-κB signaling (DiPerna et al., 2004) is truncated in MVA in
comparison to other orthopoxvirus N1L proteins (Antoine et al., 1998).
MVA also lacks the M2L gene, which was recently shown to inhibit
viral induction of ERK2-mediated NF-κB activation in HEK 293T cells
(Gedey et al., 2006).
The conservation of genes encoding these inhibitory proteins
among most of the orthopoxviruses suggests that fundamental
properties of orthopoxvirus structure or replication may intrinsically
provide stimuli that can activate NF-κB signaling pathways. The
nature of the responses to infectionmay then be governed both by the
capacity of the cell to sense and transduce these stimuli, and by the
presence or absence of viral inhibitory factors. Whilst the activation of
NF-κB, and the ensuing immune responses, may be detrimental to
poxviral replication in vivo, such stimulation of immune responses
may be beneﬁcial in humans when induced by a replication-impaired
vaccine virus, such as MVA (reviewed by Pickup (2007)). For this
reason, a greater understanding of the viral factors contributing to the
activation and suppression of NF-κB in response to orthopoxvirus
infections should assist the development of more effective poxviral
vaccines.
Results
Early events in MVA replication induce NF-κB activation
The object of this study was to identify elements of virus–cell
interactions that contribute to orthopoxvirus-induced activation of
NF-κB signaling pathways. MVA infection of HEK 293 cells provides a
useful experimental system with which to study this process. In this
system, we previously demonstrated that MVA infection, (i) induced
IκBα degradation, (ii) caused the accumulation of nuclear NF-κB
capable of binding DNA fragments containing NF-κB binding sites, and(iii) induced the transcription of reporter genes under the control of
NF-κB-regulated promoters (Oie and Pickup, 2001). The degradation
of IκBα provides a sensitive and rapid measure of early events in the
activation of the classical NF-κB signaling pathway. Therefore, in this
study, IκBα degradation was used as the primary indicator of the
effects of MVA infection upon the activation of NF-κB.
Analyses of the kinetics of activation of NF-κB signaling after MVA
infection of HEK 293T cells showed that IκBα degradation occurs
between 1 and 2 h after inoculation, with degradation continuing
through 4 h post-inoculation (Fig. 1A). Subsequently, the IκBα is
partially replenished, and from 8 h post-inoculation up to 24 h post-
inoculation, IκBα is maintained in amounts less than those in mock-
inoculated cells. At this later stage, the IκBα in the infected cells is
refractory to further depletion in response to treatment with either
additional virus, or exogenous TNFα (data not shown).
To conﬁrm that events during the early phase of virus infection are
sufﬁcient to induce IκBα degradation, we examined the effects of MVA
infection on IκBα degradation in the presence or absence of cytosine
arabinoside (AraC), an inhibitor of viral DNA synthesis. Incubation of
mock-inoculated (uninfected) cells in the presence of AraC did not
cause detectable IκBα degradation over the time course of the
experiment (data not shown). In contrast, MVA-infected cells
incubated in the presence of AraC exhibited IκBα degradation that
was similar to that in virus-infected cells that were not treated with
Fig. 2. IκBα depletion is not induced by infection with UV-inactivated MVA. HEK 293T cells were mock-infected (M) with PBS, or infected with MVA incubated with psoralen cross-
linker followed by 0, 2, 4, or 6 min of UV irradiation. The quantity of virus used in each inoculumwas equivalent to that of 20 pfu/cell before UV irradiation. At 1, 2, 3, and 4 h post-
infection, cells were harvested and cytoplasmic extracts were prepared. Proteins in the extracts were resolved by PAGE, and transferred to nitrocellulose membranes. IκBα was
detected with rabbit antibody against human IκBα and visualized by ECL. Equal protein loading and efﬁcient transfer were veriﬁed using the ﬂuorescent SYPRO Total Protein Stain.
The infectious titers (pfu/ml) of each inoculum after UV-irradiation were determined by plaque assay in BHK21 cells.
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infection cycle, preceding viral DNA replication and late gene
expression, is sufﬁcient to trigger IκBα degradation.
To determine whether protein synthesis was required for MVA-
mediated induction of NF-κB signaling, virus infections were carried
out in the presence of cycloheximide. The protein synthesis inhibitor
was added to the cells at the same time as the virus. Under these
conditions, IκBα degradation was still induced by virus (Fig. 1C). This
suggests that neither viral nor cellular protein synthesis is necessary
to induce IκBα degradation. However, in the presence of cyclohex-
imide, IκBα degradation occurred with similar kinetics, but to a lesser
extent than occurred in the absence of cycloheximide, suggesting that
factors arising from the continued cellular protein synthesis and the
progression of virus replication to the late phase contribute to the
continued degradation of IκBα during the course of the infection.
During this period, as the physiological state of the infected cell
changes, viral or cellular protein synthesis may provide additional
stimuli or factors that promote or enhance IκBα degradation.
The apparent lack of requirement for viral protein synthesis to
initiate virus-induced IκBα degradation raised the possibility that
direct interactions between the virus particles and the host cell might
be sufﬁcient to induce IκBα degradation. Virus particles can be
photochemically inactivated, without affecting their structure, by
treatment with the cross-linking agent psoralen and long-wave
ultraviolet (UV) irradiation (reviewed by Hanson (1992)). When
applied to vaccinia virus, limited UV-psoralen treatment leads to a loss
of infectivity, as with increasing duration of the cross-linkingFig. 3. Expression of the cowpox virus CP77 gene enables MVA protein synthesis in CHO cells.
CP77, which expresses the CP77 gene (each infection at 20 pfu/cell). At the indicated times p
cells were incubated in medium containing [35S]-labeled methionine and cysteine. After 30
were resolved by SDS-PAGE through an 8-16% polyacrylamide Tris-glycine gradient gel (Invit
The gels were then dried, and radiolabeled proteins were visualized by autoradiography. Thtreatment there is progressively greater inhibition of viral gene
expression (Tsung et al., 1996). Accordingly, MVA was incubated with
psoralen, and equal aliquots were subsequently irradiated with long-
wave UV light for periods of up to 8 min. The aliquots of MVA were
used to inoculate HEK 293T cells to determine the effect of UV-
psoralen treatment on virus-induced IκBα degradation. The amounts
of infectious virus remaining in each aliquot were determined by
titration on BHK cells. As shown in Fig. 2, the extent of IκBα
degradation was directly related to the infectious titer of the
inoculum. Although the cell cultures each received equivalent
amounts of virus particles, degradation of IκBα occurred only in
cells that received infectious virus particles, suggesting that virion
components alone delivered to the cells do not activate NF-κB
signaling in HEK 293T cells.
Together, these results indicate that events occurring early after
the initiation of virus infection are necessary and sufﬁcient to induce
NF-κB signaling upon MVA infection of HEK 293T cells. The
requirement for infectious virions, together with the ability of MVA
to induce IκBα degradation in the presence of cycloheximide,
implicate viral early RNAs as prime candidates for stimulating NF-κB
activation.
Viral host-range proteins inhibit MVA-induced depletion of IκB
The genome of MVA comprises only a subset of the genes present
in other orthopoxviruses (Antoine et al., 1998), suggesting that MVA-
mediated activation of NF-κB signaling may at least in part be due toCHO cells were mock-infected (M) with PBS, infected with MVA, or infected with MVA/
ost-infection, after a 30-min incubation in methionine-free and cysteine-free medium,
min of incubation, cells were harvested, and whole-cell lysates were prepared. Proteins
rogen). Equal protein loading was veriﬁed by Coomassie blue staining (data not shown).
e mobilities of molecular mass standards are indicated.
Fig. 4. MVA-induced IκBα degradation is inhibited by the expression of either the
cowpox virus CP77 gene or the vaccinia virus K1L gene. (A) HEK 293T cells were mock
infected with PBS, or infected with MVA, or with MVA/CP77 (20 pfu/cell). At the
indicated times post-infection, cells were harvested, and the depletion of IκBα was
monitored as described in Fig. 1A. (B) HEK 293T cells were mock infected with PBS, or
infected with MVA, or with MVA/K1L (20 pfu/cell). For a positive control, TNF-treated
cells were treated with 10 ng/ml of human TNF for 20 min before harvest. At the
indicated times post-infection, cells were harvested, and the depletion of IκBα was
monitored as described in Fig. 1A.
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Pickup, 2001). Consistent with this model, an early gene, the K1L host-
range gene (Perkus et al., 1989), which is intact in VV-WR, but
disrupted in the MVA genome, was found to be capable of inhibiting
MVA-induced NF-κB activation in HEK 293T cells (Shisler and Jin,
2004). In addition, analyses of a deletion mutant of cowpox virus
(CPXV A549), which lacks an intact copy of the cowpox virus homolog
of the vaccinia virus K1L gene, demonstrated that cowpox virus
encodes proteins other than the K1L protein, which are capable of
inhibiting TNF-induced, and possibly virus-induced, degradation of
IκBα (data not shown).
One candidate gene that is expressed by cowpox virus, but non-
functional in all characterized strains of vaccinia virus is the CP77
gene. This early gene, which corresponds to the CPXV025 gene in the
genome of CPXV-BR (Genbank accession number AF482758), has also
been referred to as the CHO host-range (CHO hr) gene, because it was
originally identiﬁed as a gene required to permit cowpox virus to
replicate in CHO cells (Spehner et al., 1988). Subsequently, it was
found that the CP77 gene could functionally substitute for the K1L
gene to permit the replication of vaccinia virus in cells of certain types
including human cells (Perkus et al., 1990; Ramsey-Ewing and Moss,
1996). Both the K1L protein and the CP77 protein were shown to
overcome host-range restriction during the early phase of vaccinia
virus replication in RK13 cells, consistent with their function being toFig. 5. MVA-induced IκBα degradation is impaired in CHO cells and RK13 cells by the
expression of the CP77 gene. CHO or RK13 cells were mock infected (M), or infected
with MVA or MVA/CP77 (20 pfu/cell). At the indicated times post-infection, cells were
harvested, and the depletion of IκBα was determined as described in Fig. 1A.prevent the inhibition of translation (Drillien et al., 1978; Ramsey-
Ewing and Moss, 1996; Sutter et al., 1994). Further, Hsiao et al. (2004)
had noted both that the infection of HeLa cells with a vaccinia virus
deletion mutant lacking 18-kbp of the viral genome, including the K1L
and C7L host-range genes, resulted in the rapid induction of
phosphorylation of PKR and eIF2α, and that these effects were
suppressed by the expression of the CP77 gene. These observations
suggested that the CP77 protein might possess many of the same
properties as the K1L protein, including an ability to inhibit virus-
induced IκBα degradation.
To test this hypothesis, a recombinant virus (MVA/CP77) was
constructed, in which the disrupted CP77 gene in the MVA genome
was replaced by a copy of the functional gene from cowpox virus.
Analyses of protein synthesis in CHO cells infected with either MVA or
MVA/CP77 conﬁrmed that the substitution of the cowpox virus gene
conferred the expected host-range phenotype on the recombinant
MVA. The presence of a functional CP77 gene enabled the recombinant
MVA to both suppress the rapid inhibition of protein synthesis
induced by the unmodiﬁed virus, and permit the synthesis of early
and late viral proteins (Fig. 3). Further analysis of MVA/CP77
conﬁrmed that the repair of the CP77 gene permitted the recombinant
MVA virus to replicate both in CHO cells and RK13 cells (data not
shown). In contrast to MVA, MVA/CP77 did not induce the depletion
of IκBα in virus-infected HEK 293T cells (Fig. 4A). Indeed, the MVA/
CP77 virus behaved similarly to recombinant virus MVA/K1L (virus
A664) in which the disrupted K1L gene has been repaired (Fig. 4B).
These results showed that the functional similarities between
CP77 and K1L genes noted previously in the context of viral host-range
also extend to their abilities to inhibit MVA-induced depletion of IκBα
in HEK 293T cells. This raised the question of possible connections
between the host-range functions of these genes and their abilities to
interfere with virus-induced depletion of IκBα. However, the K1L gene
is not sufﬁcient to extend the host range of MVA to HEK 293 cells
(Carroll and Moss, 1997). In these and other human cells, the primary
restriction on MVA replication appears to be not the expression of
viral genes, but the assembly of progeny virus particles (Gallego-
Gomez et al., 2003; Sancho et al., 2002; Sutter and Moss, 1992), and
this process appears to be impaired irrespective of the expression of
the K1L gene. In cells of other types that are non-permissive for MVA
or certain strains of vaccinia virus, the block in viral replication occurs
at an earlier phase of replication, where cell and viral protein synthesis
is inhibited prior to the onset of viral late gene expression, as for
example in MVA-infected CHO cells (Fig. 3). Expression of the CP77Fig. 6. MVA-induced IκBα degradation is impaired in MEFs lacking PKR. PKR0/0 and
PKR+/+ MEFs were mock infected (M) with PBS, or infected with MVA (20 pfu/cell).
At the indicated times post-infection, cells were harvested, and the degradation of
IκBα was monitored as described in Fig. 1A. (B) MVA-induced IκBα degradation in
PKR0/0 MEFs is restored by expression of human PKR. BAC 7 cells, which are PKR0/0
MEFs that express the human PKR gene, and BAC 10 cells, which are PKR0/0 MEFs that
contain an unexpressed human PKR gene, were mock infected (M) with PBS, or
infected with MVA (20 pfu/cell). At the indicated times post-infection, cells were
harvested, and the depletion of IκBα was determined as described in Fig. 1A.
Fig. 7.Host cell and viral protein synthesis is similar in PKR+/+ MEFs infected with either MVA or MVA/CP77. The PKR+/+ cells were infected (20 pfu/cell) with MVA, or with MVA/
CP77, which expresses the CP77 gene (at 20 pfu/cell). At the indicated times post-infection, after a 30-min incubation in methionine-free and cysteine-free medium, cells were
incubated in medium containing [35S]-labeled methionine and cysteine. After 30 min of incubation, cells were harvested, and whole-cell lysates were prepared. Proteins were
resolved by SDS-PAGE through a 12.5% polyacrylamide gel. Equal protein loading was veriﬁed by Pierce Gelcode blue staining (data not shown). The gels were then dried, and
radiolabeled proteins were visualized by autoradiography. The mobilities of molecular mass standards are indicated.
Fig. 8. MVA-induced IκBα depletion in PKR+/+ MEFs is impaired by the expression of
either the cowpox virus CP77 gene or the vaccinia virus K1L gene. (A) PKR+/+ cells
were infected with MVA, MVA/CP77, or MVA/K1L (20 pfu/cell). At the indicated times
post-infection, cells were harvested, and the depletion of IκBα was monitored as
described in Fig. 1A. (B) BAC 7 cells, which are PKR0/0 MEFs that express the human PKR
gene, were infected with MVA, MVA/CP77, or MVA/K1L (20 pfu/cell). At the indicated
times post-infection, cells were harvested, and the depletion of IκBα was monitored as
described in Fig. 1A. The membranes were subsequently processed for the detection of
GAPDH as controls for protein loading per lane.
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et al., 1988). Similarly, expression of the K1L gene alleviates this block
to MVA replication in RK13 cells (Meyer et al., 1991). The growth
phenotypes of MVA/K1L and MVA/CP77 in RK13 cells and CHO cells
were similar to those reported previously for MVA/K1L recombinants
or equivalent VV-WR recombinants expressing the K1L or CP77 genes
(Perkus et al., 1990; Carroll and Moss, 1997). While MVA cannot
productively infect either RK13 cells or CHO cells, MVA/K1L was able
to productively infect RK13 cells, and MVA/CP77 could productively
infect cells of either type. As in cells of other types, MVA infection of
RK13 cells or CHO cells induced the depletion of IκBαwithin 2 h post-
infection, whereas after infection with MVA/CP77, there was less
depletion of IκBα in CHO cells (about 20–30% of original levels
remaining at 4 h post-infection), and no detectable depletion of IκBα
in RK13 cells (Fig. 5).
Accordingly, there is a correlation between the expression of the
K1L and CP77 host-range genes, and the inhibition of virus-induced
depletion of IκBα. However, MVA replicates in BHK cells where virus-
induced IκBα depletion occurs (Oie and Pickup, 2001). This suggests
that the pathways leading to viral activation of NF-κB signaling, and
the pathways leading to host-range restriction may be divergent or
separate. The host-range proteins may separately affect these path-
ways, or they may produce the observed effects on each pathway by
targeting components common to each pathway.
The double-stranded RNA activated protein kinase, PKR, is required for
MVA-induced IκBα degradation in mouse embryo ﬁbroblasts
There are a number of possible mechanisms through which MVA
might induce NF-κB signaling via viral early RNAs. One potential
mechanism is via Toll-like receptors (TLRs), which can detect a wide
variety of agonists, including components of virus particles and
nucleic acids, to induce signaling leading to the activation of NF-κB
(reviewed by Barton (2007); Bowie and Haga (2005); Finberg and
Kurt-Jones (2004)). However, TLR-mediated induction of NF-κB
signaling is unlikely both because HEK 293T cells are not responsive
to most TLR agonists unless TLRs are adventitiously expressed in these
cells, and because orthopoxviruses, including MVA, encode inhibitors
of TLR-induced signaling pathways. The main alternative mechanismof signal induction is via intracellular nucleic acid sensors such as the
RIG-I related RNA helicases, and PKR (reviewed by Bowie and
Fitzgerald (2007); Garcia et al. (2007); Meylan and Tschopp
(2006)). In particular, PKR has long been known to mediate IκBα
degradation and NF-κB activation (Kumar et al., 1994), and to be
targeted for inhibition by proteins encoded by various orthopox-
viruses (Beattie et al., 1991; Chang et al., 1992; Davies et al., 1992,
1993). This prompted us to determine if PKR might be one of the
factors involved in the induction of NF-κB signaling by MVA.
Transgenic mice homozygous for a deletion of exons 2 and 3 in the
PKR gene (PKR0/0 mice) have been generated, and cells from these
182 H.E. Lynch et al. / Virology 391 (2009) 177–186mice were shown to express no detectable PKR protein (Yang et al.,
1995). To determine if PKR is involved in MVA-induced IκBα
depletion, embryonic ﬁbroblasts derived from these PKR0/0 mice, or
PKR wild-type (PKR+/+) control mice, were infected with MVA (Fig.
6A). Depletion of IκBα occurred in MVA-infected PKR+/+ cells with
kinetics similar to those of IκBα depletion in MVA-infected HEK 293T
cells, occurring between 1 and 2 h after infection, and maintained
through 4 h post-infection. In contrast, MVA infection of PKR0/0 cells
did not result in detectable depletion of IκBα (Fig. 6A), which suggests
that functional PKR is required for MVA-induced depletion of IκBα.
To conﬁrm that the phenotype seen in PKR0/0 mouse cells was
speciﬁcally due to the absence of functional PKR, we performed a
rescue experiment, using derivatives of these cells that either stably
express (Hu PKR+), or do not express (Hu PKR−), the wild-type
human PKR gene (Deb et al., 2001; Yang et al., 1995). MVA infection of
Hu PKR− cells resulted in no detectable depletion of IκBα (Fig. 6B),
whereas MVA infection of Hu PKR+ cells resulted in a rapid and
sustained depletion of IκBα (Fig. 6B), similar to that seen in MVA-
infected PKR+/+ cells.
Although MVA infection of PKR+/+ cells results in the depletion of
IκBα, both early and late viral genes appear to be expressed, and
unlike in CHO cells (Fig. 3), in these PKR+/+ cells, MVA-mediated
expression of the CP77 gene had no discernible effects on cellular or
viral protein synthesis (Fig. 7). These results are consistent with those
of Ludwig et al., 2006, who showed that MVA directed expression of
both intermediate and late genes in both PKR+/+ and PKR 0/0 cells.
Thus, all temporal classes of MVA genes are expressed in these MEFs
either in the presence or the absence of PKR, and irrespective of MVA-
induced depletion of IκBα.
Collectively, these results show that one mechanism of MVA-
induced depletion of IκBα during the early phase of virus replication is
dependent upon PKR. The infection of either PKR+/+ (wt) cells, or Hu
PKR+ cells, with either MVA/CP77 or MVA/K1L resulted in the
inhibition of MVA-induced depletion of IκBα (Fig. 8), consistent with
a role for each of the CP77 and K1L proteins in the inhibition of PKR-
mediated IκBα depletion.
Discussion
This study and earlier studies have shown that orthopoxviruses
can induce NF-κB signaling upon infection (Gedey et al., 2006; Guerra
et al., 2004, 2006; Oie and Pickup, 2001; Shisler and Jin, 2004).
Induction is dependent upon the viral species, viral strain, and the
cell-type, suggesting that induction of the NF-κB transcription factors
might be a contributory factor to the differences in the pathogenic and
immunogenic properties of the various orthopoxviruses.
The transient nature of IκBα depletion induced by virus infection
of these cells is similar to that induced by TNFα in uninfected cells
(reviewed by Hoffmann et al. (2006); Moss et al. (2008); Scheidereit
(2006)), except that in the latter, the IκBα is replenished within about
90 min (Oie and Pickup, 2001). The more prolonged period of
depletion of IκBα by virus infection may occur because of continued
stimulation post-infection, or viral inhibition of host protein synthesis,
which would be expected to reduce the capacity of the infected cell to
replace the degraded IκBα or synthesize NF-κB to stabilize IκBα
(Mathes et al., 2008). Virus infection may also interfere with other
processes involved in the cellular suppression of NF-κB signaling,
including the nuclear export of NF-κB/IκB complexes (Moss et al.,
2008), and the expression or the functions of negative-feedback
regulators of NF-κB signaling, such as host-cell deubiquitinating
enzymes (Enesa et al., 2008; Heyninck and Beyaert, 2005).
The results of this study demonstrate that one mechanism by
which MVA can initiate a signaling pathway leading to the activation
of NF-κB is through a PKR-dependent process stimulated by an early
event during viral replication. This result is consistent with results of
several previous studies showing that PKR is both one of the majorintracellular sensors of virus replication, and a factor capable of
inducing the activation of NF-κB (reviewed by Garcia et al. (2006)).
MVA infection is capable of inducing IκBα degradation and NF-κB
signaling in HEK 293T cells, whereas several other orthopoxviruses,
including vaccinia virus (WR), raccoonpox virus, and cowpox virus
(BR) do not cause a similar induction. MVA may have a greater
capacity to activate the PKR-mediated pathway of NF-κB signaling
than some of the other orthopoxviruses. In addition, it may lack some
of the capacities of other orthopoxviruses to inhibit PKR-mediated
processes. One indication that MVA may have a greater capacity to
initiate NF-κB activation than some of the other orthopoxviruses is
that MVA induces IκBα degradation even in the presence of
cycloheximide, whereas cowpox virus induces little if any IκBα
degradation under similar conditions (Oie and Pickup, 2001). This
suggests that irrespective of the presence or absence of viral inhibitors
of NF-κB signaling, these two viruses differ in their abilities to
stimulate signaling.
Our results are consistent with those of previous studies indicating
that vaccinia virus has the capacity to induce PKR activation. In
particular, with respect to MVA, recently Ludwig et al. (2006)
demonstrated that infection of various human cells, or MEFs, with
MVA (MVAΔE3L) lacking the E3L gene induced the activation of PKR.
Infection with MVAΔE3L resulted in the inhibition of translation of
viral intermediate mRNAs. The K3L protein appears to play a
secondary role to E3L, because in a variety of human cells and MEFs,
in the absence of E3L, the K3L protein does not appear to be sufﬁcient
to suppress phosphorylation of eIF2α. Thus, MVA has both the
capacity to induce PKR-mediated effects, and, through E3L and K3L
proteins, the capacity to suppress at least some of these effects. The
observed cell-type speciﬁc nature of this mechanism of MVA-
mediated activation of PKR-dependent NF-κB signaling may in part
reﬂect differences among the properties of PKR-dependent signaling
pathways in cells of different types (Langland and Jacobs, 2002).
The nature of the stimuli responsible for MVA-mediated activation
of IκBα degradation has yet to be determined. Double-stranded RNA
(dsRNA) is a prime candidate for the stimulus, because this is one of
the major inducers of PKR (reviewed by Garcia et al. (2007)). Ludwig
et al. (2006) suggested that one potential source of the MVA-
mediated activation of PKR might be dsRNAs generated by the
transcription of viral intermediate genes, because dsRNAs were
readily detectable among these mRNAs. Our results show that MVA
can activate PKR-mediated signaling pathways even in the absence of
viral DNA replication, suggesting that early viral events may provide
the ﬁrst stimuli to induce PKR-mediated host responses to viral
infection. Whilst the majority of complementary RNAs capable of
forming dsRNAs are produced during the intermediate and late phases
of virus replication, there is evidence that vaccinia virus infection may
generate smaller amounts of dsRNAs at early times during infection
(Boone et al., 1979; Colby et al., 1971). These small quantities of early
viral dsRNAs might be capable of triggering host responses to
infection. Initial evidence to this effect was provided by Kibler et al.
(1997), who noted that although AraC had no effect on apoptosis in
mock-infected cells or in cells infected with wild-type virus, apoptosis
was induced in HeLa cells infected with VV-Cop (VVΔE3L) lacking the
E3L gene even in the presence of AraC, albeit at a reduced amount in
comparison to that in cells infected in the absence of AraC. They
suggested that the reduced apoptotic response in AraC-treated cells
might be the result of a reduced amount of dsRNAs in VVΔE3L-
infected AraC-treated cells versus untreated cells. Further, early viral
RNA synthesis was found to be necessary for vaccinia virus induction
of the rapid cessation of protein synthesis in non-permissive CHO cells
(Drillien et al., 1978).
One possible contributory factor that might differentiate MVA
from many other orthopoxviruses with respect to its ability to induce
PKR-mediated signaling at early times might be its capacity to
generate complementary early RNAs. Through its extended passage
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structure, or transcriptional control elements, permitting more
extended early transcription of complementary regions than other
orthopoxviruses.
Anothermajor difference betweenMVA and other orthopoxviruses
that do not induce the early activation of PKR signalingmay be the lack
of a full complement of genes in MVA encoding viral inhibitors of
cellular sensors of viral infection. Although MVA encodes both the E3L
and K3L inhibitors of PKR, it has been shown to lack a number of
orthopoxvirus genes known to encode inhibitors of various pathways
of NF-κB activation. It lacks the vaccinia virus A52R gene, which
encodes a protein that can disrupt signaling mediated by IRAK2 and
TRAF6 (Harte et al., 2003). It lacks a functional version of the vaccinia
virus K1L gene, which encodes a protein capable of suppressing MVA-
induced activation of NF-κB (Shisler and Jin, 2004). It lacks a
functional version of the vaccinia virus M2L gene, which encodes a
protein capable of suppressing MVA-mediated activation of NF-κB via
an ERK2-dependent pathway (Gedey et al., 2006). And, although it
contains an open reading frame capable of encoding a protein similar
(141/149 residues identical) to the vaccinia virus B14 protein that can
interfere with IkappaB kinase Beta activity (Chen et al., 2008), it is not
known if this variant protein is functional in MVA. In this study, we
have conﬁrmed a role for the K1L gene in suppressing MVA-mediated
activation of NF-κB. In addition, we have shown that the cowpox virus
CP77 gene, which can functionally substitute for the K1L gene to
permit replication of MVA in RK13 cells, also can suppress MVA-
induced degradation of IκBα. Our results suggest a role for each of
these host-range proteins in the suppression of virus-induced
activation of PKR-mediated signaling pathways. Interestingly, such a
role also provides a potential explanation for onemechanism of action
of these host-range proteins in extending viral host range, because
PKR is one of the primary effectors of the virus-induced inhibition of
protein synthesis that can render cells refractory to viral replication.
Therefore, the results suggest a model whereby through the inhibition
of PKR-mediated functions, the K1L and CP77 proteins may each
contribute not only to the suppression of viral NF-κB activation, but
also to the suppression of PKR-mediated processes contributing to
host-range restriction of virus replication. Whether or not the K1L and
CP77 proteins interfere with the activation of other PKR-mediated
antiviral processes, such as the activation of p38 mitogen-activated
protein kinase (Goh et al., 2000), and the induction of interferon
regulatory factors 1 and 3 (Kirchhoff et al., 1995; Kumar et al., 1997;
Zhang and Samuel, 2008) remains to be determined.
In most natural orthopoxvirus infections, the early induction of
PKR-mediated responses leading to the activation of NF-κB-mediated
transcription, and cell-type speciﬁc inhibition of protein synthesis
would be expected to adversely affect viral replication in vivo, as
suggested by the altered properties and attenuation of vaccinia viruses
lacking the E3L gene (Brandt et al., 2005; Brandt and Jacobs, 2001;
Deng et al., 2006; Langland et al., 2006; Ludwig et al., 2006; Zhang and
Samuel, 2008). However, these same properties may be highly
advantageous for a vaccine virus (Jentarra et al., 2008; Vijaysri et al.,
2008). The unusual ability of MVA to induce early-phase PKR-
mediated responses leading potentially both to the stimulation of
immune responses, and to the impairment of virus replication, may
prove to be one of the principal factors contributing to the efﬁcacy and
the safety of this vaccine virus.
Materials and Methods
Cells and viruses
Syrian baby hamster kidney 21 (BHK21) cells were maintained in
minimum essential media (MEM) alpha (Gibco, Grand Island, NY)
supplemented with 5% fetal bovine serum (FBS; Sigma, St. Louis, MO).
HEK 293T cells and BSC40 cells were maintained in MEM (Gibco) with10% FBS. Human osteosarcoma (143B) cells were maintained in MEM
supplemented with 5% FBS. Chinese hamster ovary K1 (CHO) cells
were maintained in F-12 Kaighn's media (F-12 K; Gibco) supplemen-
tedwith 10% FBS. Rabbit kidney (RK13) cells weremaintained inMEM
supplemented with non-essential amino acids (Gibco) and 10% FBS.
Mouse embryonic ﬁbroblast (MEF) cells derived from PKR+/+ and
PKR0/0 mice as described by Yang et al. (1995) were grown in
HGDMEMwith 10% FBS. Bac7 and Bac10 cells (Deb et al., 2001), which
are PKR0/0 MEF cells containing bacterial artiﬁcial chromosomes
(BAC) harboring the human PKR gene that is expressed or not
expressed, respectively, were maintained in HGDMEM supplemented
with 200 μg/ml of Zeocin (Invitrogen, Carlsbad, CA) and 10% FBS.
Viruses employed in this study were: A660, a plaque-puriﬁed
isolate derived from MVA obtained from Dr. B Moss, (NIH); A392, a
plaque-puriﬁed isolate of the VV-WR strain; CPXV-BR, cowpox virus
Brighton red strain; A665, the MVA/CP77 virus, which is MVA
containing the CPXV-BR CP77 gene in place of the disrupted MVA
counterpart to this gene; A664, the MVA/K1L virus that contains a
functional VV-WR K1L gene in place of the disrupted MVA K1L gene.
Antisera and other reagents
IκBαwas detected using a rabbit, polyclonal, anti-IκB-α (C-21) IgG
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Donkey, anti-
rabbit-horseradish peroxidase (HRP) conjugate was from Amersham
(Piscataway, NJ). GAPDH was detected with HRP-conjugated mouse
monoclonal antibody to human GAPDH (Abcam, Cambridge, MA).
Rabbit, polyclonal, anti-vaccinia virus (strain Lister) antibody was
obtained from Biodesign International (Saco, ME). Recombinant,
human, TNFα (R&D Systems Inc., Minneapolis, MN) was reconstituted
at a concentration of 10 μg/ml in sterile phosphate buffered saline
(PBS) with 0.1% bovine serum albumin (BSA). Cycloheximide and
cytosine arabinoside (AraC) were obtained from Sigma. Psoralen
(trioxsalen, 4′-aminomethyl-, hydrochloride; Calbiochem, San Diego,
CA) was reconstituted in dimethyl sulfoxide at a concentration of
2.5 mg/ml, and stored at 4 °C.
Virus stock preparation and virus puriﬁcation
MVA was puriﬁed through three rounds of plaque puriﬁcation in
BHK21 cells, cultured, puriﬁed, and quantiﬁed in these cells as
described (Carroll and Moss, 1997; Earl et al., 1991). MVA/CP77 and
MVA/K1L (A664) viruses were plaque-puriﬁed and cultured as
described (Staib et al., 2004). CPXV-BR was cultured in human 143B
cells.
Ultraviolet (UV) inactivation of MVA
MVA was inactivated by UV irradiation as described (Humlova
et al., 2002). Brieﬂy, aliquots of 1.5×108 pfu from a lysate MVA stock
were each brought to a volume of 1ml in Hank's Balanced Salt solution
with 0.1% BSA and psoralen at a ﬁnal concentration of 2 μg/ml. The
aliquots were incubated at room temperature for 10 min in 3.5 cm2
dishes. After this time, one aliquot was transferred to a 1.5ml tube and
put on ice while the other aliquots were put under 365 nm UV light
from a UV lamp (Model UVGL-58, UVP, San Gabriel, CA) held at a
height of 3 in. After various (2–8) min of exposure to UV, each aliquot
was removed. The aliquots of virus were used either for titration in
BHK21 cells, or for the infection of HEK 293T cells.
Preparation of whole-cell and cytoplasmic extracts
Extracts were prepared by methods similar to those described
(Dignam et al., 1983; Laegreid et al., 1994). Whole-cell lysates were
made by lysing cells for 1–5 min on ice in 50–100 μl of sample buffer
containing 60 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT,
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protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN),
20 mM β-glycerophosphate, 10 mM NaF, and 1 mM Na3VO4. The
whole-cell extracts were then boiled for 5 min, vortexed, and stored at
−20 °C. Cytoplasmic extracts were prepared as described (Oie and
Pickup, 2001).
Western blot analysis
Proteins from equal amounts of cells were separated by SDS-PAGE
(Laemmli, 1970) in 8–16% polyacrylamide gels. Proteins were then
transferred to nitrocellulose membranes in transfer buffer (25 mM
Tris, 192 mM glycine, 20% methanol, 0.1% SDS; pH 8.2). To conﬁrm
equal protein loading and transfer among samples, the proteins were
visualized by staining with SYPRO Ruby Total Protein Stain (Sigma) as
follows. PAGE-resolved proteins were ﬁxed to the membranes for
15 min in a 10% methanol, 7% acetic acid solution, and then washed
four times with double-distilled H2O (ddH2O) for 5 min. The
membranes were then stained for 15–20 min with SYPRO Ruby Total
Protein Stain. After ﬁve 1-min washings with ddH2O, the proteins on
the membranes were visualized by UV illumination. To visualize
speciﬁc proteins of interest, the membranes were then blocked
with 5% milk in Tris-buffered saline with 0.05% Tween-20 (TBST) for
30–60 min at room temperature. The membranes were incubated in
5% milk/TBST at a 1:5000 dilution for 2 h to overnight with primary
rabbit antibodies against proteins of interest. Membranes were
washed three times for 5 min with TBST before incubation with the
secondary antibody, a donkey anti-rabbit-HRP conjugate, at a dilution
of 1:5000 in TBST for 1–1.5 h. After four 10-min washes with TBST,
the proteins were detected using enhanced chemiluminescence
(ECL Plus kit; Amersham, Pittsburgh, PA). Alternatively, for detection
of GAPDH as a gel loading control, after protein transfer to the
membranes, the membranes were blocked with Pierce Superblock
plus 0.05% Tween (Superblock-T) for 1 h at room temperature. The
IκBα was detected with a 1: 5000 dilution of rabbit anti-IκBα
antibodies incubated in 20% Superblock-T solution at 4 °C overnight.
Bound antibodies were detected with anti-rabbit-HRP conjugate, at a
dilution of 1:10000 in 20% Superblock-T after development with
Pierce SuperSignal West Pico chemiluminescent substrate. When
probing the same blot for GAPDH, the HRP-conjugated to antibodies
on the blot was inactivated by incubating the membrane at 65 °C
in TBS for 1 h, then reblocking for 30 min, followed by incubation
with 1:40,000 anti-GAPDH mAB in Superblock-T solution for 1 h at
room temperature.
Pulse-labeling experiments
Cells were labeled by adding Promix (Amersham), containing [35S]
radiolabeled methionine and cysteine, directly to the growth medium
(15 μCi/ml) for 30 min before harvesting the cells. Before adding the
Promix, growthmediumwas removed, andmethionine- and cysteine-
free medium (Gibco) was added. To harvest, the medium containing
radiolabel was removed, and the cells were lysed in whole-cell lysis
buffer.
Plasmid and recombinant virus constructs
Plasmid constructs were generated using standard techniques.
Restriction enzymes were obtained from New England Biolabs, Inc.
(Beverly, MA). DNA fragments were ampliﬁed using the polymerase
chain reaction (PCR) in the Applied Biosystems GeneAmp PCR System
2400 (Applied Biosystems, Branchburg, NJ). PCR was done using 30
cycles of 30 s at 94 °C, 30 s at 55 °C, and 1 min 30 s at 72 °C. The
Advantage HF-2 Polymerase kit (BD Biosciences, Palo Alto, CA) was
used in high-ﬁdelity PCR ampliﬁcation for cloning purposes. PCR for
construct screening was done using the AmpliTaq DNA Polymerase kitfrom Applied Biosystems. DNA fragments were isolated from agarose
gels using the QIAEX II Gel Extraction Kit (QIAGEN, Germantown,
MD). For ligations, the Rapid DNA Ligation Kit (Roche Diagnostics,
Indianapolis, IN) was used. Construction of plasmids was veriﬁed
using sequence analysis, which was performed by the Duke University
DNA Analysis Facility. Oligonucleotide primers were generated by IDT
(Coralville, IA) or Operon Biotechnologies, Inc. (Huntsville AL).
The MVA/K1L (A664) virus was constructed as follows. PCR was
used to generate a 1403-bp DNA fragment containing VV-WR K1L
gene ﬂanked by an upstream sequence corresponding to 522-bp at the
3′-end of N2L ORF in the MVA genome. An insertion vector containing
this construct was used to replace the disrupted K1L gene present in
MVA, with selection for the recombinant MVA/K1L virus in RK13 cells
as described (Staib et al., 2004). The purity of the ﬁnal plaque-puriﬁed
isolate was conﬁrmed by PCR using primers that ﬂanked the K1L gene.
Subsequently, the virus was cultured in RK13 cells.
The MVA/CP77 virus was constructed as follows. The 2287-bp
NdeI–HpaI fragment of CPXV-BR DNA (present in plasmid p62)
containing the CP77 gene was subcloned into plasmid vector pYes2, to
make plasmid pYes2–25. This NdeI–HpaI fragment was transfected
into MVA-infected BHK cells, and recombinant MVA viruses capable
of replicating in CHO cells were isolated and plaque-puriﬁed in RK13
cells. The purity of the ﬁnal plaque-puriﬁed isolate was conﬁrmed
both by PCR using primers that allowed us to distinguish between the
intact CP77 gene and the disrupted MVA homolog of this gene, and by
DNA hybridization analyses, as described (Southern, 1975). A probe
was used that corresponded to the CP77 gene and about 100 bases of
ﬂanking sequence. The radiolabeled probe was generated using the
NEBlot kit (New England Biolabs) according to manufacturer's
instructions. The probes were isolated from free label using the
Promega Wizard DNA Clean-up kit, according to manufacturer's
instructions. The probes were denatured by boiling for 5 min, then
quenched by adding to the 5× SSC/5× Denhardt's/0.5% SDS
hybridization buffer. Hybridizations of the probes to the immobilized
DNAs were done at 65 °C overnight. The membranes were washed
four times for 10 min at 65 °C with 500 ml of 2× SSC/0.1% SDS, and
then wrapped in plastic ﬁlm. The annealed probes were visualized by
autoradiography.
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